Skip to main content
Have a personal or library account? Click to login
Evolving sociodemographic trends with survival analysis in lung carcinoma: 6-year insight from Regional Cancer Center (RCC) of North India Cover

Evolving sociodemographic trends with survival analysis in lung carcinoma: 6-year insight from Regional Cancer Center (RCC) of North India

Open Access
|Mar 2026

Figures & Tables

Figure 1:

Percentage-wise distribution of types of carcinoma lung cases from 2015 to 2020 at Regional Cancer Center, Rohtak (Haryana), India.

Figure 2:

Stage-wise distribution of patients of carcinoma lung at Regional Cancer Center from 2015 to 2020.

Figure 3:

Kaplan–Meier survival curve depicting comparison of overall survival of carcinoma lung patients at Regional Cancer Center from 2015 to 2020.

Lung cancer demographics and survival outcome reported among various studies in India_

Region/state (year of publication)Number of patientsMale: femaleMean/median ageSmokers’ percentageHistology (most common)Median OS (months)
Mohan et al (8)Delhi (2019)18624.86:15876.2Adenocarcinoma (34%)8.8
Krishnamurthy et al (16)Tamil Nadu (2012)2583.5:15660.5Adenocarcinoma (42.6%)Not analyzed
Kaur et al (7)Chandigarh (2017)13014.6:158.676.9Squamous cell carcinoma and adenocarcinoma (34.6%)Not analyzed
Sheikh et al (17)Kashmir (2010)7836.98:157.868.1Squamous cell carcinoma (71.3%)Not analyzed
Mandal et al (6)Manipur (2013)4661.09:158.573Squamous cell carcinoma (49.1%)Not analyzed
Rajappa et al (18)Hyderabad (2008)1944:158 10.6965Not analyzed (studied only NSCLC)7 (2–72)
Gupta et al (19)Jammu and Kashmir (2015)1706.5:155.9479.4Squamous cell carcinoma (45.3%) and adenocarcinoma (35.3%)Not analyzed
Murali et al (9)Tamil Nadu6783.195853.4Adenocarcinoma (51.1%)7.6 (NSCLC) and 7.2 (SCLC)
Dey et al (5)Eastern India (2012)6074.14:156.5573.2Squamous cell carcinoma (35.1%)Not analyzed
Garg et al (12)North India (2021)5373.59:16066.5Adenocarcinoma (51.2%) Only NSCLC analyzed11.7 (95% CI: 5.5–29.9 months)
Vasudevan et al (20)North India (2022)7243:16059.1Adenocarcinoma (56.6%)11.9 months
Darling et al (21)Delhi (2020)1362.48:16065.4Adenocarcinoma (44.9%)Not analyzed
Ramani et al (22)Bangalore (2020)12462.95:161Not reportedAdenocarcinoma (70.4%)Not analyzed
Bhatti et al (23)North India (2020)1992.8:160.9 ± 11 yearsNot reportedSquamous cell carcinoma (37.7%), followed by adenocarcinoma (26.1%)Not analyzed
Chordia et al (24)Jalgaon, Maharashtra (2019)866.16:156 (Median)63.95Adenocarcinoma (56.97%) followed by squamous cell carcinoma (25.58%)Not analyzed
Thakkar et al (25)Gujarat (2019)509:159.9292Adenocarcinoma 36% followed by squamous cell carcinoma (32%)Not analyzed
Present studyHaryana3765.2:159.5285.9Squamous cell carcinoma (41.5%)4.6 months

Demographic indices of carcinoma lung patients and their correlation with survival_

Demographic IndicesNo. of patientsPercentage (%)Mean OS (months)Median OS (months)p-Value
Gender
Females6116.225.33 (1–6)0.661
Males31583.784.83 (1–7)
Age (years)
≤6020253.725.5 (0.4–84)30.588
>6017446.284.1 (0.3–22)2
Residential status
Rural29979.525.13 (1–7)0.158
Urban7720.4843 (0.55–5)
Smoking status
Nonsmokers4813.034.623.3 (1–9.25)0.318
Smokers32085.906.372 (1–7.5)
Ex-smokers81.0653 (1–6.75)
ECOG PS
0, 151.36.57<0.001
214438.36.94.5
318148.13.92
44612.21.50.8
Stage-wise analysis
Non-small cell carcinoma
Stage II61.6011.590.01
Stage III13134.846.34
Stage IV18047.873.83
Small cell carcinoma
Stage III256.654.83
Stage IV318.244.572
SVC syndrome
Any stage30.800.81
Type of malignancy
Small cell carcinoma5614.894.520.413
Non-small cell carcinoma31784.3153
Squamous cell carcinoma15641.494.33
Adenocarcinoma11731.127.15
Adenosquamous carcinoma10.2744.044
Large cell carcinoma71.867.37
Unspecified318.242.61
Others51.338.16
SVC syndrome30.800.40.4

Gender, survival, and histopathologic variation among smokers versus nonsmokers_

No of patientsMales/femalesMean survivalMean smoking indexSmCACSCCAdenosquamousLCCUnspecifiedOthersSVC syndrome
Smokers320303/174.62724.574986143162843
Nonsmokers485/436.37-630900210
Ex-smokers87/15558.811401100
DOI: https://doi.org/10.2478/fco-2024-0021 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Language: English
Submitted on: Apr 4, 2025
Accepted on: Nov 4, 2025
Published on: Mar 28, 2026
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2026 Garima Malik, Shailley, Ashok K. Chauhan, Paramjeet Kaur, Rajeev Atri, Rakesh Dhankar, Narayan P Patel, N. Balasubramanian, Sachin Sehgal, Rakesh Malik, Aman Sachdeva, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

AHEAD OF PRINT